TGA Documents Hospitalisations as Peptide Adverse Effects Rise
The TGA has documented hospitalisations and serious adverse effects from unapproved peptides, while Google runs ads for substances banned under Australian law.
Australia’s Therapeutic Goods Administration has documented a growing list of serious adverse effects linked to unapproved peptide products, including hospitalisations from severe allergic reactions. The disclosure, made through a TGA safety alert in April 2026, came as a Sydney Morning Herald investigation revealed that Google was running paid advertisements for peptides that cannot legally be promoted in Australia.
What the TGA Safety Alert Found
The TGA safety alert reported that the agency had received reports of severe allergic reactions requiring hospitalisation among users of unapproved peptide products. Additional reported adverse effects included blurred vision, flu-like illnesses, severe inflammation, muscle injuries, and insomnia.
The alert specifically named products including BPC-157, GHK-Cu, TB-500, retatrutide, and CJC-1295 as compounds linked to these reports. None of these products have been assessed by the TGA for safety, quality, or effectiveness, and most are classified as Schedule 4 (prescription-only) substances under Australian law.
The TGA noted a significant increase in both the promotion and use of unapproved peptide products, including injectable formulations marketed for anti-ageing, bodybuilding, tanning, and weight loss. The agency attributed much of this increase to social media promotion and influencer marketing.
The Google Advertising Problem
A Sydney Morning Herald investigation published in April 2026 found that Google was hosting dozens of advertisements for synthetic peptides in breach of its own policies and Australian advertising laws. The investigation found ads for BPC-157, a prescription-only peptide, and GHK-Cu, an unapproved substance, appearing as sponsored results on Google search.
Under the Therapeutic Goods Act 1989, advertising unapproved therapeutic goods to the public is prohibited. Google’s own advertising policies similarly prohibit the promotion of unapproved pharmaceutical supplements.
A Google spokesperson told the SMH that the ads breached the company’s policies and that it had conducted a “thorough investigation into these ads and accounts and taken the appropriate action where necessary.” However, the masthead confirmed that other peptide ads remained live on the platform at the time of publication.
Google’s own internal data underscores the scale of the trend. Searches for “peptides” on the platform increased 30 per cent in the past year. Searches for retatrutide, an experimental weight loss drug currently in phase 3 clinical trials but freely sold online, increased by 900 per cent. Searches for GHK-Cu rose 450 per cent.
A Pattern of Enforcement Gaps
The gap between regulatory rules and platform enforcement is not new, but the peptide category is testing its limits. The TGA has issued multiple public warnings about unapproved peptide products, yet the supply chain remains largely intact. Products are readily available online, can be purchased without medical oversight, and are delivered by post within days.
Adjunct Associate Professor Katinka van de Ven from the University of New South Wales, who specialises in drug policy, told the SMH that one of the biggest unknowns in the peptide debate was the actual size of the Australian market. Without that data, she said, it was difficult to design effective policy responses.
The TGA’s adverse effects reports suggest the consequences of the current gap are already materialising in emergency departments. The documented cases of hospitalisation from severe allergic reactions point to quality and contamination risks that are inherent in unregulated supply chains, where products may contain undeclared ingredients, incorrect concentrations, or manufacturing contaminants.
What Researchers and Buyers Should Know
For researchers procuring peptide compounds, the TGA’s adverse effects data reinforces the critical importance of verified certificates of analysis from accredited laboratories. The difference between a research-grade product and a grey-market consumer product is not merely regulatory, it is a matter of what is actually in the vial.
The University of Queensland’s Dr Timothy Piatkowski, lead author of a recent JAMA manuscript on the peptide grey market, has called for evidence-based harm reduction guidance and population-level surveillance to track adverse events. His team is now working on an international cohort study across Australia, Canada, and the United States.
The TGA continues to encourage consumers and healthcare professionals to report adverse events associated with any therapeutic product through its online reporting system.
Sources
- TGA, Safety Alert: Unapproved peptide products, April 2026
- Sydney Morning Herald, “Searches up 900%: Google faces influx of illegal peptide ads,” 20 April 2026
- ABC 7.30, “Sport Integrity Australia to widen drug-testing amid illicit peptides boom,” 21 May 2026
- Nutrition Insight, “Gray market peptides blur drug and supplement distinctions, raising health risks,” 9 July 2026
For educational purposes only. This content is informational and reflects publicly reported developments. It is not legal, medical, or regulatory advice. Consult a qualified professional for compliance questions.